








Scabies is a well-known, yet a poorly understood neglected tropical disease 
(NTD). Although less common in the UK, scabies epidemics regularly occur 
abroad, in tropical, less developed communities (LDCs). Cases are prevalent in 
communities which tend to live with overcrowding, poor sanitation and limited 
access to healthcare facilities and medication. This environment provides the 
perfect breeding ground for the growth and the transmission of scabies. The 
body has a delayed response to infestation - this is due to the scabies mites’ abil-
ity to disrupt the complement cascade and delay the onset of the adaptive arm of 
the immune response.
Relevance
Contrary to popular belief, anyone can become infested with scabies. Although 
not usually life-threatening, scabies can cause unpleasant symptoms as well as 
worsen existing skin conditions, which can reduce a person’s quality of life. 
Prompt diagnosis is challenging in LDCs. Undiagnosed scabies may lead to 
serious complications such as secondary skin sepsis as well as allowing further 
transmission. Scabies is highly contagious; clinicians should be aware how to 
spot and treat scabies early on, and additionally know to o!er treatment to other 
individuals that the patient has been in close contact with. 
Take Home Messages
Management for scabies is relatively simple and involves the application of topical 
medication, such as Permethrin. Despite this, there are still many barriers to 
treating epidemics in LDCs, such as a lack of access to treatment and healthcare 
professionals, a lack of awareness from clinicians about the condition’s clini-
cal manifestations, as well as lack of infrastructure to de"nitively diagnose the 
condition. Despite progress in management of the condition, the pathophysiol-
ogy and transmission of the condition are only partly understood, and the rise 
of resistance to current scabicides is indicative of the need for newer treatments, 
especially within resource-poor communities. 
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The World Health Organisation (WHO) de"nes neglected tropical 
diseases (NTD) as ‘a diverse group of communicable diseases that 
prevail in tropical and subtropical conditions in 149 countries.’ (1) 
It is currently estimated that NTDs a!ect over 1 billion people, 
the majority of which live in less developed communities (LDCs), 
which have a lack of sanitation and healthcare access. This lack of 
access facilitates the spread of communicable diseases, potentially 
leading to preventable complications, such as blindness, physical 
deformities, and neurological problems. (2) The grouping of NTDs 
has led to their increased awareness amongst clinicians and has pro-
vided a compelling platform to derive speci"c management plans. 
Recent evidence has suggested that investments addressing NTDs 
is cost-e!ective for developing economies. More people cured will 
ensure a larger, healthier work force, consequently boosting the 
economy of developing nations. (3)
 
There are currently 17 NTDs including the well-known skin 
disease scabies. Skin diseases are one of the most frequent reasons 
for GP consultation. Skin diseases represented 8.4% of German 
consultations in 2010, with this set to increase globally. (4) Most 
patients with dermatological problems are only treated by their GP 
and are not referred further. (5) Although the prevalence of scabies 
in the UK is low, the condition still has global importance. There-
fore, all clinicians should be aware of scabies, as well as understand 
how to diagnose and treat it, due to its profound impact on the skin. 
Skin protects internal organs, thermoregulates, allows sensation, 
forms vitamin D and therefore regulates calcium and phosphate 
levels in the body, acts as a physical barrier to the entry of foreign 
substances/ pathogens and is aesthetically important. (6)
Scabies is de"ned in two major forms, ordinary scabies (OS) and 
the more severe, crusted scabies (CS). (7) Both manifest from the 
same species of mite, thus management and treatment are largely 
the same between the conditions. This piece aims to discuss the 
epidemiology, transmission, clinical manifestation, and the patho-
physiology of scabies, as well as the body’s subsequent immunologi-
cal response to the disease. In addition, this piece will describe the 
use of mass drug administration (MDA) as a treatment in LDCs 
with a scabies endemic, before brie#y outlining the future of the 
methods of diagnosis and management of scabies. 
Epidemiology 
Scabies predominantly a!ects children and the elderly in the devel-
oping world, regardless of gender or race. Regions with the highest 
prevalence of scabies include India, the South Paci"c and Northern 
Australia (which includes the Aboriginal community, which has 
the highest prevalence for CS). Communities based in these densely 
populated, tropical areas tend to live with overcrowding, poor 
sanitation and limited access to healthcare facilities and medication. 
This environment provides the perfect breeding ground for the 
growth and the transmission of scabies. (9, 10) In the UK, members 
of lower socioeconomic households/communities are more likely 
to experience some of the e!ects of relative poverty. These e!ects 
include inadequate access to health facilities and treatment, a poor 
level of hygiene, the sharing of unclean clothing, bedding or towels 
may facilitate transmission of scabies, malnutrition, and illiteracy. In 
addition, frequent population movements also facilitate the spread 
of the infestation. Though the exact prevalence of CS is unknown, 
it is thought to be rare; however, on several occasions, local epidem-
ics of OS have originated from a single case of CS. (11)
There is a notable correlation between overcrowding and the preva-
lence of scabies. Overcrowding facilitates the rapid spread within a 
population. (10, 12) Additionally, the cases of scabies #uctuate de-
pending on seasonal changes. A Russian study found that between 
the months of September and December, the fertility of scabies 
mites (and thus the incidence of scabies) was greater compared to 
the months of January to July (fertility index scores of 11.5 versus 
8.9, respectively). (13) Further "ndings exempli"ed that scabies 
mite oogenesis arrest tends to be greater during the former half of 
the year, which subsequently leads to a seasonal decrease in the local 
scabies mite population which may cause a decreased incidence of 
scabies over the summer period. (13, 14) Finally, it is also important 
to note that a lack of healthcare and education regarding the condi-
tion and general hygiene inevitably mean that cases go untreated, 
contributing to its transmission and prevalence. 
In the UK, the overall prevalence of scabies is 2.81 per 1,000 
females and 2.27 per 1,000 males. Although relatively uncommon, 
children between the ages of 10 and 19 experience the highest in-
festation rates. There is a signi"cantly greater infestation rate among 
females with a relative risk of 1.24 (p < 0.001) compared to males. 
(15) 
Transmission 
Scabies is a parasitic infection, caused by Sarcoptes scabiei var 
hominis (S. scabiei). These mites burrow into the stratum corneum 
of the epidermis of the skin, where the microenvironment is ideal 
for the parasite to remain and lay its eggs. This subsequently leads to 
an immune response from the host. This process is summarised in 
Figure 1. 
Figure 1: 







Common sites S.scabiei mites are found, as well as sites of rashes.
Common sites of rashes and mite habitation can be seen in Figure 
2; it includes areas such as the groin, shins, and armpits. (16) Ex-
tensive skin-to-skin contact with a person who has scabies is the 
most common form of transmission. Transmission may also occur 
via contact with items such as clothing, bedding, or towels that 
have been used by a person with scabies (more common in CS), or 
by having sexual intercourse with someone with the disease. (17) 
Based on this, it is understandable why those in LDCs experience 
the highest rates of prevalence, as transmission is exacerbated by 
overcrowded conditions that people may live in, as well as a general 
lack of sexual health awareness that may contribute to the spread 
of disease. Within 15 to 20 minutes of exposure, S. scabiei can 
in"ltrate the skin and subsequently initiate its life cycle. The time 
taken for the onset of clinical manifestations a$er initial exposure 
may be up to eight weeks. (16) A correct diagnosis may be further 
delayed due to a lack of awareness from clinicians, as the signs and 
symptoms of scabies can mimic several other forms of skin disease, 
leading to a misdiagnosis. Further barriers to a rapid diagnosis 
include the lack of access to a hospital/GP and a lack of equipment 
that some practices may have to examine the patient. (18) 
Clinical Manifestation and Diagnosis 
One of the "rst symptoms of OS is a rash at the sites shown in 
Figure 2, and an intense pruritus, which typically worsens at night. 
At early stages of the condition (when scabies mites lay eggs in the 
skin), silvery lines with a dot at one end can be seen on the skin. As 
the rash spreads, it begins to present as tiny red spots. (17) A rash 
and pruritus are normally absent in CS; CS presents di!erently in 
that it presents more severely. There are many more mites in the 
skin, leading to CS being typically characterised by thick crusts 
of the skin, with a grey discolouration. (19) In CS, breached areas 
of the skin may exhibit erythema, which predisposes patients to 
secondary bacterial infection from Staphylococcus aureus and S 
pyogenes, (20) as well as causing skin infections like impetigo and 
worsening any existing eczema or psoriasis. (17)
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 Diagnosis of scabies is usually based on the history of the presenting 
symptoms. It is important to also take a social and family history in 
these cases, so that clinicians may understand if the condition has 
been spread via a family member. The presence of mite burrows in 
the skin are infrequently seen in OS, (7) so doctors may use other 
methods to achieve a de"nitive diagnosis. Methods may include 
dermatoscopy, but due to the equipment required this is infeasible 
in many remote areas, or a skin scrape, which involves scraping 
a blade coated with oil across a burrow and then examining the 
collected sample microscopically. Finally, scabies could also be 
diagnosed in remote communities via a ‘burrow ink test:’ a lesion 
suspected to be caused by scabies is covered in ink and then rubbed 
o! the patient using alcohol. For a scabies-positive result, an ink 
tracking would remain in the burrows. (7)
Pathogenesis 
Innate, humoral, and cellular responses are thought to play a sig-
ni"cant role in the body’s response to scabies. The immunological 
response is more apparent in patients with CS compared to OS, 
as the high mite count proportionally induces a stronger response. 
(21) A su%cient immune response is only generated 4-6 weeks a$er 
initial contact is made, partly due to genetic changes involved in 
epithelium development and partly because of the mite’s ability to 
modulate gene expression via the expression of inhibitor proteins, 
thus delaying an innate immune response. (22) Once detected 
however, the body can overcome the condition, with assistance 
from medication. On the other hand, the doctor should feel the 
patient is su%ciently informed of the above to make a personalised 
decision. They should appreciate what the patient would consider 
a good outcome. They should understand what risks are important 
to that patient. They should have taken the opportunity to apply 
these factors to their recommended management plan. They should 
understand why a patient has come to a particular decision.
Innate immune response 
The S. scabiei present in the stratum corneum is detected by two 
of the three complement-activating pathways: the classical and alter-
nate pathway, which are activated by antigen-antibody complexes 
and endotoxins. (23) This leads to activation of the complement 
cascade, which produces the compounds C3a, C3b, C4a and 
C5a. The formation of these compounds eventually leading to the 
following outputs: chemotaxis of neutrophils and eosinophils to 
the parasite, mast cell activation, cell lysis and opsonisation of the 
parasite, which makes it more vulnerable to destruction by the 
immune system. The overall e!ect of these outputs is the priming 
of an adaptive immune response, which includes the mobilisation 
of a high number of eosinophils (responsible for the anti-helminth 
response) towards S. scabiei. When several of these eosinophils 
attach to the mites, they release compounds such as peroxidase, 
ribonuclease, and major basic protein, all of which contribute to 
killing the mites and their eggs. (24) S. scabiei have evolved to evade 
the complement cascade, via the production of two proteins: scabies 
mite serine protease inhibitor B3 and 4 (SMSB3 and SMSB3). (25) 
Both proteins bind directly to complement proteins, inhibiting their 
action in a way that all three complement-activating pathways are 
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disrupted. (26) This results in a temporary delay in the recruitment 
of eosinophils and a delay in the activation of the adaptive immune 
response. Consequently, S. scabiei can survive and multiply in the 
host longer.
Adapative immune response 
The adaptive immune response must be launched to allow a host to 
overcome scabies. The role of the adaptive immune response be-
comes apparent when the numbers of Th2 lymphocytes increase in 
response to the parasite. The Th2 cell in turn secretes interleukins 
4, 5 and 13 (IL-4, IL-5 and IL-13). Among other things, IL-4 pro-
motes class switching of antibodies produced by plasma cells into 
di!erent isotypes, notably, immunoglobulin E (IgE). IL-5 promotes 
the recruitment of eosinophils towards the site of infection, and 
IL-13 is responsible for expelling the parasite from the body once it 
has been killed. (27) There is an association between the presence 
of scabies and increased levels of antigen-speci"c IgE. (28)
IgE is a glycoprotein that speci"cally binds to target parasitic anti-
gens. E!ector functions of the antibody are normally mediated via 
the fragment crystallisable (Fc) region. It is this region which the 
eosinophils bind to, using the Fc RI receptors on their surface. 
Only when this binding occurs can the eosinophil begin to act on 
the parasite to kill it. (29) The antigen-binding fragment (FAB) of 
IgE binds to the corresponding receptor antigen on S. scabiei. Its 
high a%nity results in numerous IgE antibodies coating S. scabiei. 
This is summarised in Figure 3. The interaction between the in-
nate immune system and the humoral arm of the adaptive immune 
system allows the body to overcome the infestation. 
Treatments and further developments 
In the UK, the two most widely used treatments for scabies are 
Permethrin and Malathion. Both medications are to be applied 
topically and contain insecticides that kill the scabies mite. Of the 
two medications, Permethrin 5% cream is usually recommended 
as the "rst-line treatment; Malathion 0.5% lotion is administered 
if permethrin is ine!ective. (30) Clinicians ask patients to apply the 
medication to their whole body, from the neck down, and leave it 
on for at least 8-10 hours (some treatments may also require a sec-
ond application). (31) Clinicians should also recommend treatment 
for all the people the patient has been in close contact with, even if 
they show no signs of scabies infestation; this is due to the conta-
gious nature of the condition.
The WHO recommends mass drug administration (MDA) as a 
method to treat and control outbreaks of scabies in LDCs. MDA 
involves treating every member within a de"ned population and 
location (unless speci"cally contraindicated) with scabicides, 
without individual diagnosis. In endemic areas, it aims to reduce 
transmission and alleviate symptoms of those infested. (32) A study 
conducted in rural Fiji tested the e!ectiveness of MDA, using 
Permethrin as medication. The trial was conducted in 2012 for 12 
months and involved 2051 participants in total. It found that those 
who underwent MDA had a statistically signi"cant 62% reduction 
in cases of scabies from baseline. (33) Though this study, along with 
others, suggest that MDA is e!ective in LDC, a limitation to this 
model regards population movement between an area which had 
been treated with MDA to scabies-prevalent areas, which may lead 
to re-infestation. 
As mentioned above, there are several di%culties in promptly 
diagnosing scabies in LDCs. However, recent advancements in 
diagnosis may assist this issue. A study by Jayaraj and colleagues 
investigated the potential of using IgE antibodies which are speci"c 
to recombinant Sar s 14.3 (rSar s 14.3), a major antigen of scabies. 
This immunological assay was quanti"ed and assessed. The diag-
nostic e%ciency of rSar s 14.3 detecting active scabies infestation 
was extremely high, with a 100% sensitivity and 93.75% speci"city 
to patients with scabies. This shows great potential as a test for sca-
bies. (34) Nonetheless, it is still in its early stages of development, 
and appears to be resource intensive, which may be a problem for 
resource de"cit countries.
&"
Scabies has been brought back to the attention of clinicians world-
wide when the WHO categorised it as one of 17 NTDs. Although 
not usually life-threatening, scabies can cause symptoms which can 
reduce a person’s quality of life. Undiagnosed, scabies may lead to 
serious complications such as secondary skin sepsis, as well as dev-
astatingly vast transmission in densely populated areas. Problems in 
LDCs include the di%culty surrounding diagnosis due to a lack of 
awareness about the condition, as well the scabies mite’s adaptations 
to evade the immune system. Despite progress in the management 
of the condition, the pathophysiology and transmission of the con-
dition are only partly understood. The rise of resistance to current 
scabicides is indicative of the need for newer treatments, especially 
within resource poor communities.
Figure 3:  
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